argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
argenx SE (ARGNF) - Total Assets
Latest total assets as of June 2025: $7.18 Billion USD
Based on the latest financial reports, argenx SE (ARGNF) holds total assets worth $7.18 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
argenx SE - Total Assets Trend (2014–2024)
This chart illustrates how argenx SE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
argenx SE - Asset Composition Analysis
Current Asset Composition (December 2024)
argenx SE's total assets of $7.18 Billion consist of 78.7% current assets and 21.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.2% |
| Accounts Receivable | $817.71 Million | 13.2% |
| Inventory | $407.23 Million | 6.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $181.44 Million | 2.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how argenx SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: argenx SE's current assets represent 78.7% of total assets in 2024, a decrease from 98.1% in 2014.
- Cash Position: Cash and equivalents constituted 24.2% of total assets in 2024, down from 55.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
argenx SE Competitors by Total Assets
Key competitors of argenx SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
argenx SE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - argenx SE generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, argenx SE generates $ 13.43 in net profit.
argenx SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.60 | 8.53 | 9.90 |
| Quick Ratio | 5.27 | 7.88 | 9.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.79 Billion | $ 3.76 Billion | $ 1.76 Billion |
argenx SE - Advanced Valuation Insights
This section examines the relationship between argenx SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.89 |
| Latest Market Cap to Assets Ratio | 6.93 |
| Asset Growth Rate (YoY) | 36.5% |
| Total Assets | $6.20 Billion |
| Market Capitalization | $42.99 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values argenx SE's assets at a significant premium ( 6.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: argenx SE's assets grew by 36.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for argenx SE (2014–2024)
The table below shows the annual total assets of argenx SE from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.20 Billion | +36.55% |
| 2023-12-31 | $4.54 Billion | +44.93% |
| 2022-12-31 | $3.13 Billion | +9.96% |
| 2021-12-31 | $2.85 Billion | +24.75% |
| 2020-12-31 | $2.28 Billion | +59.41% |
| 2019-12-31 | $1.43 Billion | +147.79% |
| 2018-12-31 | $578.46 Million | +55.96% |
| 2017-12-31 | $370.91 Million | +250.67% |
| 2016-12-31 | $105.77 Million | +130.13% |
| 2015-12-31 | $45.96 Million | -21.45% |
| 2014-12-31 | $58.51 Million | -- |